MORRISVILLE, N.C.,— May 9, 2012—TearScience®, a privately held medical device company, today announced that it sponsored research for seven scientific posters on evaporative dry eye and its technology, at the 2012 Association for Research in Vision and Ophthalmology (ARVO) annual meeting being held from May 6-10, 2012, in Fort Lauderdale, Florida. Subjects reflect new, ongoing research on the disease, TearScience®’s technology, and clinical outcomes. The posters cover topics such as how the LipiFlow® Thermal Pulsation System can rejuvenate Meibomian gland secretions for up to a year as well as LipiFlow’s efficacy and safety over warm compress therapy for treating Meibomian gland dysfunction. Another demonstrates LipiView Ocular Surface Interferometer’s ability to consistently and accurately measure the thickness of thin film, optically similar to the tear film. Additional research presented increases the general understanding of normal Meibomian gland function and eye lid physiology and interaction.
“TearScience is committed to furthering the research, knowledge, understanding and treatment of evaporative dry eye disease,” said Tim Willis, CEO of TearScience. “Our posters are a reflection of our culture of ongoing research and innovation. Our mission is to provide the most relevant and profitable products to physicians so they can provide improved care and optimize outcomes for the millions of patients who suffer from evaporative dry eye.”
ARVO’s mission is to encourage and assist research, training, publishing and disseminating knowledge in vision and ophthalmology. Its multidisciplinary membership consists of scientist, clinicians and basic researchers.
TearScience’s system includes two medical devices, the LipiView® Ocular Surface Interferometer and the LipiFlow® Thermal Pulsation System. Evaporative dry eye occurs when Meibomian glands in the eyelids become obstructed and do not secrete the oily lipids needed to keep the water portion of tears from evaporating too quickly. LipiView® captures detailed digital images to allow physicians to assess a dry eye patient’s tear film while the LipiFlow® treats evaporative dry eye disease by unblocking obstructed Meibomian glands located in the eyelids during a 12-minute in-office procedure. The goal of unblocking the glands is to allow them to resume their natural production of lipids needed for a healthy tear film.
About TearScience, Inc.
Headquartered in Morrisville, North Carolina, TearScience has pioneered devices that provide significant clinical improvement in the treatment of evaporative dry eye. Of the more than 100 million dry eye sufferers worldwide, approximately 86 percent have evaporative dry eye, which is caused by Meibomian Gland Dysfunction (MGD) and a lipid deficiency of the eye’s natural tear film. The Tear Film and Ocular Surface Society (TFOS) workshop, involving two years of work by 50 leading experts from around the world, concluded that MGD is an under-estimated condition and is very likely the most frequent cause of dry eye disease. Common symptoms of the disease include eye irritation, dryness, redness, tiredness, and visual disturbances. TearScience’s integrated, in-office system enables eye care professionals to effectively address a root cause of evaporative dry eye, obstructed Meibomian glands. For additional information, visit www.tearscience.com.
# # #